Journal
MOLECULAR GENETICS AND METABOLISM
Volume 113, Issue 1-2, Pages 131-135Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymgme.2014.06.005
Keywords
Urea cycle disorder; Sodium phenylbutyrate; Branched-chain amino acids
Funding
- NIH Office of Rare Diseases Research (ORDR) [U54HD061221]
- National Center for Advancing Translational Science (NCATS) [U54HD061221]
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [U54HD061221]
- NIH [DK92921]
- Baylor College of Medicine General Clinical Research Cente [RR00188]
- BCM Intellectual and Developmental Disabilities Research Center from the Eunice Kennedy Shriver National Institute of Child Health & Human Development [HD024064]
- ACMG Foundation/Genzyme Biochemical Genetics Fellowship
- Doris Duke Charitable Foundation
Ask authors/readers for more resources
Sodium phenylbutyrate (NaPBA) is a commonly used medication for the treatment of patients with urea cycle disorders (UCDs). Previous reports involving small numbers of patients with UCDs have shown that NaPBA treatment can result in lower plasma levels of the branched-chain amino acids (BCAA) but this has not been studied systematically. From a large cohort of patients (n = 553) with UCDs enrolled in the Longitudinal Study of Urea Cycle Disorders, a collaborative multicenter study of the Urea Cycle Disorders Consortium, we evaluated whether treatment with NaPBA leads to a decrease in plasma BCAA levels. Our analysis shows that NaPBA use independently affects the plasma BCAA levels even after accounting for multiple confounding covariates. Moreover, NaPBA use increases the risk for BCAA deficiency. This effect of NaPBA seems specific to plasma BCAA levels, as levels of other essential amino acids are not altered by its use. Our study, in an unselected population of UCD subjects, is the largest to analyze the effects of NaPBA on BCAA metabolism and potentially has significant clinical implications. Our results indicate that plasma BCAA levels should to be monitored in patients treated with NaPBA since patients taking the medication are at increased risk for BCAA deficiency. On a broader scale, these findings could open avenues to explore NaPBA as a therapy in maple syrup urine disease and other common complex disorders with dysregulation of BCAA metabolism. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available